It has been an exciting month for HAVN Life Sciences (CNSX: HAVN) (OTCMKTS: HAVLF). In the news, HAVN just announced a strategic partnership with TheraPsil, the shipment of white label natural health products to their Australian distribution partner, and a supply agreement with Atman Retreat. We’re pleased to welcome HAVN CEO Tim Moore back to The Dales Report to discuss these updates, the company’s revenue potential, and more.
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products. Be sure to check out the full episode above, but here’s a few highlights:
HAVN Strikes A Partnership With TheraPsil
TheraPsil is a small non-profit coalition dedicated to helping Canadians in medical need access legal, psilocybin-assisted psychotherapy and medical psilocybin through the special access program (SAP).
With this new partnership in play, the next step is having HAVN naturally-derived psilocybin approved by Health Canada to be a candidate for their special access program so that trained physicians and clinicians can actually prescribe it. This is a large and important first step for revenue generation at home for HAVN Life Sciences.
Health Canada just last week issued guidelines for participating in the special access program, and they included both naturally-derived and synthetic psilocybin, as well as all the steps for approval. Moore says it’s very comprehensive and mostly laid around having GMP practices. Since HAVN uses these systems already, he is confident HAVN will meet the requirements of Health Canada to qualify.
Four Distribution, Partnership, Or Partnership-Expansion Deals For HAVN In The Last 2 Months
The Atman Retreat center located in Jamaica helps people explore psychedelic therapy, and HAVN has negotiated to supply naturally-derived psilocybin for use for all of their programs. This deal was one of a handful announced recently.
Importantly, Atman is operated by a Canadian-based company, and Moore feels that this will open doors to additional retreat centers down the line. Atman charges $2000-$5000 for a three day retreat, and hosts a couple dozen people in each retreat. Across Jamaica, that’s a capacity of thousands, and even more considering other resorts located across the Caribbean.
HAVN ‘One Of The Few’ In Revenue Next Year
Moore says that HAVN will be one of the few psychedelic companies in revenue in 2022. That sets the company apart because they’ve based themselves on a supply chain to deliver products to other companies using it. This includes retreats, psychedelic assisted therapy, and new drug development, and there’s a great deal of potential to increase from there.
The nutritional supplement business is also treating HAVN well, Moore says, and they’re seeing growth and increased traction with retailers who have ecommerce. They have begun delivering their white label products to Australia, to their partner, and there’s significant growth coming in 2022.